US DOJ and FTC intensely scrutinise mergers in technology and pharmaceutical industries
This is an Insight article, written by a selected partner as part of GCR's co-published content. Read more on Insight
The US antitrust agencies – whose influence will soon grow thanks to revised merger guidelines – are increasingly unified in rooting out potentially anticompetitive mergers in the technology and pharmaceutical sectors.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.